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Abstract
Background: Thrombus aspiration (TA) has been shown to improve microvascular perfusion during primary
percutaneous coronary intervention (PCI) for patients with ST-segment elevation myocardial infarction (STEMI). The
objective of our study was to assess the relationship between TA and myocardial edema, myocardial hemorrhage,
microvascular obstruction (MVO) and left ventricular remodeling in STEMI patients using cardiovascular magnetic
resonance (CMR).
Methods: Sixty patients were enrolled post primary PCI and underwent CMR on a 1.5 T scanner at 48 hours and 6
months. Patients were retrospectively stratified into 2 groups: those that received TA (35 patients) versus that did
not receive thrombus aspiration (NTA) (25 patients). Myocardial edema and myocardial hemorrhage were assessed
by T2 and T2* quantification respectively. MVO was assessed via a contrast-enhanced T1-weighted inversion
recovery gradient-echo sequence.
Results: At 48 hours, infarct segment T2 (NTA 57.9 ms vs. TA 52.1 ms, p = 0.022) was lower in the TA group. Also,
infarct segment T2* was higher in the TA group (NTA 29.3 ms vs. TA 37.8 ms, p = 0.007). MVO incidence was lower
in the TA group (NTA 88% vs. TA 54%, p = 0.013).
At 6 months, left ventricular end-diastolic volume index (NTA 91.9 ml/m2 vs. TA 68.3 ml/m2, p = 0.013) and left
ventricular end systolic volume index (NTA 52.1 ml/m2 vs. TA 32.4 ml/m2, p = 0.008) were lower and infarct
segment systolic wall thickening was higher in the TA group (NTA 3.5% vs. TA 74.8%, p = 0.003).
Conclusion: TA during primary PCI is associated with reduced myocardial edema, myocardial hemorrhage, left
ventricular remodeling and incidence of MVO after STEMI.
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Background
Primary percutaneous coronary intervention (PCI) is the
mainstay of treatment in patients with ST-segment ele-
vation myocardial infarction (STEMI) [1]. Despite
advances in primary PCI and medical therapy, the inci-
dence of heart failure, re-infarction and death in these
patients remains significant [2]. No-reflow is a common
adverse event leading to worse clinical outcomes in
patients with STEMI undergoing primary PCI, with
atherothrombotic embolization being one of the contri-
buting mechanisms [3-6]. Thrombus aspiration (TA)
can theoretically protect the microcirculation from distal
embolization, however randomized clinical trials have
resulted in conflicting results [4,7-21]. In the study by
Kaltoft et al. [13], thrombectomy was associated with
increased infarct size and did not improve ST-segment
resolution. Conversely, other trials such as REMEDIA
(Randomized Evaluation of the Effect of Mechanical
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tion in Primary and Rescue Angioplasty), DEAR-MI
(Dethrombosis to Enhance Acute Reperfusion in Myo-
cardial Infarction) and TAPAS (Thrombus Aspiration
During Percutaneous Coronary Intervention in Acute
Myocardial Infarction) showed that thrombectomy
improved microvascular perfusion. However, the impact
of TA on other parameters of microvascular injury such
as myocardial edema and hemorrhage was not addressed
in any of these trials.
Cardiovascular magnetic resonance (CMR) represents
the gold-standard method in assessing myocardial
edema, myocardial hemorrhage, left ventricular remodel-
ing and microvascular obstruction (MVO) [22-24]. The
purpose of this study was to evaluate the relationship
between TA as adjunctive therapy in primary PCI for
patients with STEMI, and myocardial edema, myocardial
hemorrhage, left ventricular remodeling and MVO.
Methods
Study population
Sixty patients presenting to Sunnybrook Health Sciences
Centre in Toronto, with STEMI between July 2009 and
March 2011 were enrolled. The main inclusion criteria
were patients that met the standard diagnostic criteria
for STEMI [25]. All patients had undergone primary
PCI as part of a regional program that triages patients
with STEMI to our centre for early revascularization.
Exclusion criteria included hemodynamic instability
(defined as systolic blood pr e s s u r e<9 0m m H g ,u s eo f
inotropic agents or an intraortic balloon pump), signifi-
cant arrhythmias, significant renal dysfunction (esti-
mated glomerular filtration rate < 30 mL/min), and
typical contraindications to CMR such as pacemakers
and implantable cardioverter-defibrillators. We obtained
written consent from all patients, and the study was
approved by the ethics review board of Sunnybrook
Health Sciences Centre.
Primary PCI protocol
All patients were pretreated prior to revascularization
with aspirin 162 mg and clopidogrel 600 mg. Choice of
anticoagulant (intravenous heparin or bivalirudin) and
optional use of glycoprotein IIb/IIIa inhibitor were left
to operator discretion. TA was performed with an
Export Medtronic device (Medtronic Inc., Minneapolis,
Minnesota) and its use was also left to operator discre-
tion. Factors influencing the use of TA included target
vessel size, degree of thrombus burden, no reflow phe-
nomenon and clinical instability. Subsequently patients
received aspirin, clopidogrel, beta-blockers, angiotensin-
converting enzyme inhibitors, angiotensin-receptor
blockers and statins as per standard of care.
Angiographic and electrocardiographic analysis
Thrombolysis In Myocardial Infarction (TIMI) flow
grade, myocardial blush grade and thrombus score were
estimated visually using previously described methods
by 2 experienced observers who were blinded to use of
TA [26-28]. ST-segment resolution, defined as ≥70%
reduction in the sum of the ST-segment elevation score
between electrocardiograms obtained before primary
PCI and immediately after the procedure, was also
recorded [29].
CMR acquisition protocol
Each patient was imaged at 2 time points: within 48
hours and 6 months post STEMI. Studies were per-
formed on a 1.5 T clinical scanner (Signa Twinspeed
HDx, GE Healthcare, Waukesha, WI) with commercially
available CMR software, electrocardiographic triggering,
8-channel receive coil and breath holds at end-expiration.
After performing a localizer scan, short-axis cine CMR
(10-12 slices) was performed with a balanced steady-
state-free-precession sequence (FIESTA, GE Healthcare)
with the following parameters: repetition time = 3.7 ms
and echo time = 1.6 ms, flip angle = 45°, slice thickness =
8 mm, acquisition matrix = 256 × 192, field of view = 35
cm, bandwidth = 125 kHz, 20 cardiac phases per slice.
Myocardial edema was assessed by T2 quantification
using a previously validated free-breathing cardiac-gated
spiral imaging sequence with T2 preparation [30,31], 8-
10 contiguous slices from base to apex and the following
typical parameters: echo times = 2.9, 24.3, 88.2, 184.2
ms, 12 spiral interleaves with 4096 points each (16.4 ms
duration), slice thickness = 6 mm, bandwidth = 125
kHz. Myocardial hemorrhage was assessed by T2* quan-
tification using a cardiac-gated spoiled gradient echo
sequence with multiple echoes, 8-10 contiguous slices
from base to apex, and the following typical parameters:
8 echoes (1.4-12.7 ms), repetition time = 14.6 ms, flip
angle = 30°, acquisition matrix = 128 × 128, 8 views-
per-segment, slice thickness = 8 mm, bandwidth = 100
kHz [31]. All echoes for a single slice were acquired in a
single breath hold. Finally, a breath-hold, contrast-
enhanced T1-weighted inversion recovery gradient-echo
sequence was used to depict the presence, location, and
extent of myocardial infarction and MVO using the fol-
lowing parameters: repetition time/echo time = 5.4/2.5
ms, flip angle = 30°, 8-10 contiguous slices from base to
apex, slice thickness = 8 mm, acquisition matrix = 192
× 128, field of view = 35 cm. The inversion time was
manually adjusted to null signal from normal myocar-
dium. Short axis images were obtained 10 minutes after
intravenous administration of Gadolinium-diethylene
triamine pentaacetic acid (0.2 mmol/kg; Gadovist, Bayer
Healthcare, Wayne, NJ).
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All cine CMR images were analyzed using QMass
® MR
software (Medis, Netherlands), and the results were the
consensus of a minimum of 2 experienced observers
who were blinded to use of TA. Endocardial and epicar-
dial borders were delineated on the end-diastolic and
end-systolic phases of short-axis slices for quantification
of left ventricular volumes, function, mass, and infarct
segment systolic wall thickening. Measurements were
indexed for body surface area. End-diastolic wall thick-
ness was measured in the infarct segment as an indica-
tor of myocardial edema in the acute phase and wall
thinning in the chronic phase. Myocardial T2 and T2*
maps were constructed by fitting signal intensities at
each pixel with an exponential model for the given echo
times. Hemorrhage was identified as an area of hypoin-
tensity on T2-weighted images within the infarcted seg-
ment. Infarct size was quantified in a contrast-enhanced
T1-weighted image using the full-width-half-maximum
technique as previously described [32] while MVO was
identified as a region of hypoenhancement within the
region of the hyperenhanced infarct, 10 minutes post
contrast administration. Infarct size, hemorrhage, and
MVO were expressed as a percentage of total myocar-
dium. Data fitting for T2/T2* maps, infarct, hemorrhage
and MVO size computation were performed with cus-
tom-written scripts developed in MATLAB
® (The
Mathworks, Natick, MA). MV Ow a sa l s or e c o r d e da sa
binary variable of being present or absent, based on the
contrast-enhanced images [33].
Statistical analysis and endpoints
The study population was divided into 2 groups: TA ver-
sus no thrombus aspiration (NTA). Primary study end
points were the degree of myocardial edema (T2 and
end-diastolic wall thickness measurements), myocardial
hemorrhage (T2* measurement) and occurrence of MVO
at the first time point of within 48 hours post-STEMI.
Secondary endpoints included the occurrence of final
myocardial blush grade ≥ 2, final TIMI flow ≥ 2 on angio-
graphy, rate of ST-segment resolution post primary PCI,
and parameters of left ventricular remodeling including
left ventricular end diastolicv o l u m ei n d e x( L V E D I ) ,l e f t
ventricular end systolic volume index (LVESI), left ventri-
cular stroke volume index (LVSVI), left ventricular ejec-
tion fraction, and infarct segment systolic wall thickening
at the final time point of 6 months post STEMI. Continu-
ous data were expressed as mean +/- standard deviation
a n da n a l y z e db yt h eS t u d e n tt test. Categorical variables
were reported as frequencies and percentages and ana-
lyzed by the chi-square or Fisher exact test, as appropri-
ate. All tests were 2-tailed, and statistical significance was
accepted at p < 0.05.
Results
Baseline characteristics
Eighty-five patients with STEMI were screened, 25
patients were excluded and 60 patients were included in
the study. Reasons for exclusion included severe renal
insufficiency, claustrophobia, hemodynamic instability
and presence of permanent pacemaker. Clinical charac-
teristics of both the TA and NTA group are shown in
Table 1 and appear to be well matched in both groups.
No difference in symptom to balloon time or door to
balloon time was observed between groups. Reasons for
not using TA by the operators included minimal throm-
bus burden visualized on the coronary angiogram, small
vessel size, or preserved distal flow throughout the pro-
cedure. Glycoprotein IIb/IIIa inhibitor use was similar in
both groups (NTA 52% vs. TA 62.9%, p = 0.514).
Angiographic, periprocedural and electrocardiographic
findings
TA was associated with more frequent final myocardial
blush grade ≥ 2 (NTA 44% vs. TA 88.6%, p < 0.01) and
ST-segment resolution (NTA 40% vs. TA 68.6%, p =
0.036) post primary PCI (Table 2). Final TIMI flow ≥ 2
was equivalent in both groups (NTA 96% vs. TA 97.1%,
p = NS).
CMR analysis
The initial CMR scan was performed at a mean of 34.4
hours post primary PCI and the second scan at a mean
of 243 days post primary PCI in the overall group.
Table 3 shows the CMR outcomes for both time points.
Figure 1 demonstrates the myocardial T2 and T2*
maps along with late gadolinium enhancement (LGE)
images in short-axis views from representative patients
in the NTA and TA groups at 48 hours. In this acute
phase, both measures of myocardial edema, i.e. infarct
s e g m e n tT 2( N T A5 7 . 9m sv s .T A5 2 . 1m s ,p=0 . 0 2 2 )
and infarct segment end-diastolic wall thickness (NTA
11.4 mm vs. TA 9.3 mm, p < 0.01), were lower in the
TA group (Table 3). Infarct segment T2* was higher,
indicative of reduced myocardial hemorrhage, in the TA
group (NTA 29.3 ms vs. TA 37.8 ms, p = 0.007). MVO
incidence was also lower in the TA group (NTA 88% vs.
TA 54.3%, p = 0.013).
Figure 2 demonstrates the LVEDVI and LVESVI mea-
surements along with LGE images in short-axis views
from patients in both treatment groups at 6 months.
Baseline LVEDVI, LVESVI, LVSVI, infarct segment sys-
tolic wall thickening, and left ventricular ejection frac-
tion measurements were similar in both treatment
groups. At 6 months, LVEDVI (NTA 91.9 ml/m2 vs. TA
68.3 ml/m2, p = 0.013) and LVESVI (NTA 52.1 ml/m2
vs. TA 32.4 ml/m2, p = 0.008) were lower in the TA
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ml/m2, p = 0.30) and left ventricular ejection fraction
(NTA 46.8% vs. TA 53.8%, p = 0.11) were equivalent in
both groups. Infarct segment systolic wall thickening
(NTA 3.5% vs. TA 74.8%, p = 0.003) and end diastolic
wall thickness (NTA 4 mm vs. TA 5.7 mm, p = 0.008)
were both greater in the TA group at 6 months.
Discussion
Our non-randomized study demonstrates that TA dur-
ing primary PCI is associated with reduced myocardial
edema, myocardial hemorrhage, infarct size, left ventri-
cular remodeling, and MVO after STEMI. We postulate
that TA results in less myocardial injury, evidenced by
the reduced infarct size, which in turn is responsible for
Table 1 Baseline Clinical Characteristics of the Study Population
Total (n = 60) NTA (n = 25) TA (n = 35) p Value
Age, yrs 59.6 ± 10.6 60.0 ± 7.3 59.5 ± 12.6 0.741
Males (%) 53 (88.3) 21 (84.0) 32 (91.4) 0.273
Diabetes (%) 15 (25.0) 6 (24.0) 9 (25.7) 0.242
Hypertension (%) 27 (45.0) 12 (48.0) 15 (42.9) 0.312
Dyslipidemia (%) 15 (25.0) 7 (28.0) 8 (22.9) 0.414
Smoking (%) 17 (28.3) 8 (32.0) 9 (25.7) 0.372
Prior Myocardial Infarction (%) 2 (3.3) 1 (4.0) 1 (2.9) 0.718
Prior PCI (%) 4 (6.7) 1 (4.0) 3 (8.6) 0.384
Creatinine, umol/L 82.1 ± 23.0 81.1 ± 17.1 82.6 ± 24.3 0.743
Symptoms to balloon, minutes 397 ± 304 402 ± 268 391 ± 291 0.831
Door to balloon, minutes 83.5 ± 51.2 83.2 ± 39.8 83.9 ± 59.8 0.765
Abbreviations. NTA no thrombus aspiration; PCI percutaneous coronary intervention; TA thrombus aspiration
Table 2 Peri-Procedural Characteristics and Outcomes of the Study Population
Total (n = 60) NTA (n = 25) TA (n = 35) p Value
Infarct artery (%)
LAD 26 (43.3) 12 (48.0) 14 (40.0) 0.344
LCx 12 (20.0) 6 (24.0) 6 (17.1) 0.210
RCA 22 (36.7) 9 (36.0) 13 (37.1) 0.416
Multivessel disease (%) 26 (43.3) 9 (36.0) 17 (48.6) 0.128
Thrombus score
2 22 (36.7) 8 (32.0) 14 (40.0) 0.224
3 23 (38.3) 11 (44.0) 12 (34.3) 0.419
4 4 (6.7) 2 (8.0) 2 (5.7) 0.426
Adjunctive Pharmacologic Therapy
Glycoprotein IIb/IIIa inhibitor (%) 35 (58.3) 13 (52.0) 22 (62.9) 0.514
Bivalirudin (%) 25 (41.7) 11 (44.0) 14 (40.0) 0.664
Stent type
Bare-metal 41 (68.3) 16 (64.0) 25 (71.4) 0.517
Drug-eluting 19 (31.7) 8 (32.0) 11 (31.4) 0.736
Mean peak creatine kinase peak (IU/L) 2177 ± 1579 2321 ± 1271 2142 ± 1643 0.513
ST-segment resolution (%) 34 (56.7) 10 (40.0) 24 (68.6) 0.036
Post PCI TIMI flow grade (%)
> 2 58 (96.7) 24 (96.0) 34 (97.1) 0.987
Post PCI MBG (%)
> 2 42 (70.0) 11 (44.0) 31 88.6) 0.001
Mean PCI to CMR time
Scan 1, hours 34.4 ± 17.3 36.6 ± 16.2 34.0 ± 17.6 0.435
Scan 2, days 243 ± 62 222 ± 52 247 ± 69 0.212
Abbreviations. CMR cardiovascular magnetic resonance; LAD left anterior descending; LCx left circumflex; MBG myocardial blush grade; RCA right coronary artery;
TIMI Thrombolysis in Myocardial Infarction; other abbreviations as in Table 1
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Scan 1
(48 Hours)
Scan 2
(6 Months)
NTA TA p Value NTA TA p Value
IS T2, ms 57.9 ± 7.9 52.1 ± 6.3 0.022 39.5 ± 3.0 40.6 ± 2.8 0.517
RS T2, ms 41.9 ± 2.7 42.4 ± 2.8 0.552 39.1 ± 2.9 39.6 ± 2.7 0.612
IS EDWT, mm 11.4 ± 2.2 9.3 ± 1.6 0.013 4.0 ± 1.1 5.7 ± 1.0 0.008
RS EDWT, mm 7.0 ± 1.4 6.9 ± 1.3 0.883 8.3 ± 1.3 7.8 ± 1.2 0.443
IS T2*, ms 29.3 ± 9.4 37.8 ± 7.0 0.007 33.9 ± 4.9 35.7 ± 5.7 0.435
RS T2*, ms 37.1 ± 3.4 38.0 ± 3.1 0.662 38.0 ± 3.7 38.2 ± 4.4 0.712
Hemorrhage, % of myocardium 11.6 ± 6.8 7.1 ± 3.8 0.02 - - -
Hemorrhage, n (%) 13 (52.0) 7 (20.0) 0.02 - - -
MVO, % of myocardium 6.7 ± 4.2 3.4 +3.1 0.003 - - -
MVO, n (%) 22 (88.0) 19 (54.3) 0.013 - - -
Infarct Size, % of myocardium 27.3 ± 9.1 19.8 ± 8.2 0.001 16.8 ± 8.7 13.8 ± 4.8 0.022
LVEDVI, ml/mm2 68.6 ± 17.6 70.4 ± 11.9 0.717 91.9 ± 21.1 68.3 ± 8.7 0.013
LVESVI, ml/mm2 37.1 ± 12.3 38.1 ± 9.9 0.873 52.1 ± 16.9 32.4 ± 5.3 0.008
LVSVI, ml/mm2 30.4 ± 9.5 32.7 ± 4.3 0.546 40.4 ± 11.2 35.8 ± 8.1 0.301
LVEF, % 44.7 ± 8.1 46.4 ± 5.9 0.392 46.8 ± 10.5 53.8 ± 7.7 0.11
IS-SWT, % 4.9 ± 24.8 -2.9 ± 18.3 0.224 3.5 ± 19.5 74.8 ± 58.5 0.003
Abbreviations. EDWT end diastolic wall thickness; IS infarct segment; IS-SWT infarct segment systolic wall thickening; LVEDVI left ventricular end-diastolic volume
index; LVEF left ventricular ejection fraction; LVESVI left ventricular end-systolic volume index; LVSVI left ventricular stroke volume index; MVO microvascular
obstruction; RS remote segment; other abbreviations as in Tables 1 and 2
Figure 1 Cardiac Magnetic Resonance Imaging Scan of Patients From Both Study Groups, No Thrombus Aspiration (NTA) and
Thrombus Aspiration (TA) at 48 Hours: show myocardial T2 and T2* maps along with late gadolinium enhancement (LGE) in short-
axis views from representative patients in the NTA and TA groups. T2 and T2* maps of the myocardium have been overlaid on T2-
weighted and T2*-weighted images. The red and blue arrows represent infarct segment (IS) and remote segment (RS) in the myocardium,
respectively. Note that edema was greater (higher T2) in the NTA patient compared to the TA patient in the IS. Lower T2* within the infarct core
(white arrow) in the NTA patient was indicative of myocardial hemorrhage and was associated with microvascular obstruction (MVO) observed
on the LGE image (white arrow)
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phase. This is the first study to use quantitative CMR
parameters to evaluate the effects of TA on myocardial
edema and myocardial hemorrhage. Recently, the utility
of quantitative CMR in the longitudinal evaluation of
myocardial edema, hemorrhage, and MVO has been
demonstrated in preclinical models of acute myocardial
infarction [31].
Both myocardial hemorrhage and MVO have been
extensively linked to worse clinical outcome post acute
myocardial infarction [22,24,33,34]. Recently, the
EXPIRA trial [17] had shown that thrombectomy
reduced the extent of MVO and infarct size after acute
myocardial infarction, which is consistent with our find-
ings. Our study had an even higher incidence of MVO
in the NTA group compared to the EXPIRA trial (88%
vs. 72.9%); however, the absolute difference between the
2 treatment groups was similar in both studies (34% vs.
41.4%).
Myocardial hemorrhage is considered to be a sign of
severe microvascular injury [35]. Histologically, it is
characterized by vascular cell damage, with leakage of
red blood cells from injured cells affecting mainly the
mid-myocardial layer [36]. It is a frequent complication
after successful myocardial reperfusion, affecting 25% of
patients, and is an independent predictor of adverse left
ventricular remodeling regardless of the initial infarct
size, and a marker of late arrhythmic risk [22,31,34].
The pathophysiology relating MVO and myocardial
hemorrhage is unclear. It is possible that MVO leads to
endothelial damage and subsequent extravasation of ery-
throcytes to the interstitium. However, it has also been
postulated that the myocardial hemorrhage causes swel-
ling of the myocardium and subsequent compression of
the microvasculature, thereby actually causing or wor-
sening MVO [37,38]. While the mechanism is uncertain,
the fact that TA is associated with a lower incidence of
MVO and reduced T2* indicating reduced myocardial
hemorrhage points to the utility of this adjunctive ther-
apy in primary PCI. Mechanical thrombus removal may
explain the better results obtained in the TA group.
Extensive preclinical and human studies have estab-
lished that T2 signal hyperintensity by CMR indicates
increased myocardial water content [39,40]. T2 may
increase within 30 minutes of ischemia onset, even
before detectable injury by troponin or late gadolinium
enhancement [41,42]. Also, end-diastolic wall thickness
h a sb e e ns h o w nt ob ea b l et oi d e n t i f ya n dm o n i t o rt h e
presence, extent and resolution of myocardial edema fol-
lowing primary PCI [43,44]. The presence of myocardial
Figure 2 Cardiac Magnetic Resonance Imaging Scan of Patients From Both Study Groups, No Thrombus Aspiration (NTA) and
Thrombus Aspiration (TA) at 6 Months: Images show a short axis slice with left ventricular end diastolic volume index (LVEDVI)
measurement in first column. Short axis slices in the second column highlight the difference in left ventricular end systolic volume index
(LVESVI) in the 2 treatment groups. Late gadolinium enhancement (LGE) images in the last column demonstrate the location of the infarct.
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recently shown to be associated with a higher hazard of
cardiovascular event or death within 6 months [45].
Hence, our observation that TA during primary PCI is
associated with reduced myocardial edema has impor-
tant clinical implications and can explain why 2 previous
randomized clinical trials h a v es h o w nar e d u c t i o ni n
major adverse cardiac events in the thrombectomy
group [17,21].
We used a quantitative T2 mapping technique to
delineate the extent of myocardial edema instead of a
T2-weighted imaging approach. T2-weighted imaging
techniques have known limitations, which impairs their
validity [39,46]. Some of these limitations include: a)
surface coil intensity inhomogeneity leading to variabil-
ity in myocardial signal, b) sub-endocardial bright signal
artifact caused by stagnant blood, c) cardiac motion
leading to reduced myocardial signal, d) subjective nat-
ure of qualitative T2-weighted imaging assessment
which then poses significant challenges in tracking long-
itudinal changes in a robust manner. Recently other stu-
dies have demonstrated that quantitative T2 mapping
addresses the known problems associated with T2-
weighted imaging and can offer increased accuracy in
the detection of myocardial edema [31,47-50].
Hemorrhage is known to not only reduce T2* values
but also T2 relaxation times [50]. An unexpected finding
in our study is that patents in the NTA group had
increased T2 relaxation times despite having more
hemorrhage. We postulate that patients in the NTA
group had more hemorrhage, more extensive myocardial
injury and therefore more edema. The fact that end-dia-
stolic wall thickness was increased acutely in the infarct
segment of the NTA group supports our hypothesis that
these patients indeed have more edema. In fact, we may
have obtained an even higher T2 value in NTA patients
if susceptibility effects of hemorrhage were not present.
In contrast to the EXPIRA [17] trial that had CMR
follow up at 3 months, we assessed left ventricular
remodeling at 6 months when infarct expansion is well
established. Using left ventricular remodeling parameters
indexed to body surface area we were able to demon-
strate a significant improvement in LVEDVI, LVESVI
and infarct segment systolic wall thickening in the TA
group. Two prior studies using echocardiography have
had conflicting results with respect to left ventricular
remodeling and use of TA. De Luca and colleagues
showed that in 76 patients with anterior myocardial
infarction, TA was associated with significantly lower
end-diastolic and end-systolic left ventricular volumes
on transthoracic echocardiography at 6 months com-
pared to conventional primary PCI [11]. In contrast,
Galiuto et al. showed no significant difference in left
ventricular volumes at 6 months with thrombectomy
using myocardial contrast echocardiography [51]. Our
significant findings in all types of infarcts, can perhaps
be explained by the superiority of CMR over conven-
tional echocardiography and myocardial contrast echo-
cardiography in terms of spatial resolution and
endocardial definition [52]. In addition, we were able to
demonstrate that TA is associated with reduced myocar-
dial hemorrhage, which in turn is an independent pre-
dictor of adverse left ventricular remodeling [34].
In accordance with the literature, TA also improved
final myocardial blush grade and the rate of ST-segment
resolution post primary PCI [11,17,18,20]. The degree of
improvement in both these parameters of microvascular
integrity was comparable to previous studies.
Study limitations
This study represents a single-centre non-randomized
experience with a limited number of patients. However,
baseline demographic and angiographic characteristics
appear to be well matched in our 2 study groups. In
particular, time to reperfusion, culprit vessel distribu-
tion, thrombus burden, enzymatic infarct size and
adjunctive glycoprotein IIb/IIIa inhibitor use were simi-
l a ri nb o t hg r o u p s .T h es a m p l es i z ei ss i m i l a rt op u b -
lished CMR studies that have investigated myocardial
edema, myocardial hemorrhage and MVO in other clini-
cal settings. TA use was left to operator discretion,
which can lead to a selection bias that may impact out-
comes. However, the lack of a trend towards a higher
thrombus burden in the TA group suggests that most of
the TA use was based on a routine use policy. Lastly,
we used a surface coil which can decrease the sensitivity
for detecting inferolateral edema and infarction with an
opposite effect in the anteroseptal region, due to an
inhomogeneous coil sensitivity profile.
Conclusions
TA as an adjunctive therapy to primary PCI is asso-
ciated with a reduction in the degree of myocardial
edema, myocardial hemorrhage, infarct size, left ventri-
cular remodeling, and MVO after STEMI. The positive
impact of TA on myocardial edema, myocardial hemor-
rhage and left ventricular remodeling using CMR is a
novel finding and therefore, we believe our data contri-
bute important findings to the current literature on this
topic. However, given the small sample size and non-
randomized design the results of our study are hypoth-
esis generating only and one cannot draw a causal rela-
tionship between favorable outcomes and use of TA in
primary PCI. The results of large randomized trials to
assess the utility of TA on the amount of salvaged myo-
cardium using CMR are pending [53,54].
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